TCGA-BH-A1EN-01A-11R-A13Q-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 71
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.550
- PROTEIN_SECRETION+0.510
- ANDROGEN_RESPONSE+0.420
- NOTCH_SIGNALING+0.400
- MTORC1_SIGNALING+0.370
- ADIPOGENESIS+0.360
- FATTY_ACID_METABOLISM+0.340
- GLYCOLYSIS+0.330
- MYC_TARGETS_V1+0.280
- MYC_TARGETS_V2+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.560
- INTERFERON_GAMMA_RESPONSE-0.430
- ALLOGRAFT_REJECTION-0.390
- IL6_JAK_STAT3_SIGNALING-0.350
- APICAL_SURFACE-0.230
- G2M_CHECKPOINT-0.230
- WNT_BETA_CATENIN_SIGNALING-0.210
- TNFA_SIGNALING_VIA_NFKB-0.180
- INFLAMMATORY_RESPONSE-0.150
- COMPLEMENT-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_TBWYAFSM | EPN | EPN Tumor | 0.836 |
| 2 | SRR10899980 | — | — | 0.809 |
| 3 | BS_TBWYAFSM | Spinal Cord Ependymoma | — | 0.807 |
| 4 | SJEPD030784_D1.RNA-Seq | EPN | Myxopapillary EPN | 0.807 |
| 5 | MNG1017 | — | — | 0.806 |
| 6 | R148 | — | — | 0.806 |
| 7 | TCGA-CV-7437-01A-21R-2132-07 | — | — | 0.790 |
| 8 | 56D3154E-E779-4C27-8305-FEE7310B6762 | — | — | 0.789 |
| 9 | MNG1041 | — | — | 0.780 |
| 10 | MNG624 | — | — | 0.771 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.550 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.510 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.420 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.360 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.330 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.240 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.130 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.110 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.100 | Inavolisib | — uncovered |